Program
polyethylene glycol-recombinant human growth hormone
Also written as “PEG-rhGH Injection”, “PEG-rhGH low dose” and “PEG-rhGH high dose”.
Its studies are mostly in Turner Syndrome, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 21 open or running | phase 2since Jun 13, 2017 | Jun 13, 2017 | Dec 23, 2026phase 2 · NCT07260500 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2017First study: phase 2 study in Turner SyndromeFirst studyNCT03189160 · 180 enrolled · China
- Nov 21, 2025Phase 2 study in Short Stature Children Born Small for Gestational Age (SGA)NCT07260500 · 72 planned · China
Ahead
- Dec 23, 2026Primary completion: phase 2 study in Short Stature Children Born Small for Gestational Age (SGA)NCT07260500
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07260500Short Stature Children Born Small for Gestational Age (SGA) · China | 2 | Recruiting | Dec 23, 2026 | 72 |
| NCT03189160Turner Syndrome · China | 2 | UNKNOWN | Mar 2018 | 180 |
How it is read
Names in the registry
- “PEG-rhGH Injection”, 1 entry
- “PEG-rhGH low dose”, 1 entry
- “PEG-rhGH high dose”, 1 entry
Conditions, from the studies’ own filings
- Turner Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.